This report from a multi-stakeholder workshop on the ‘Economics of precision medicine’ addresses the issues of cost-effectiveness, as well as the need to revise how economic and social value can be valorised and financed, and to develop new business models for fundamentally personalised gene therapies with high up-front costs.